Growth Sustained, Margins Under Pressure
Revenue beat prior guidance by 7 percentage points, but EBITDA margin compressed 40 basis points year-on-year. Management deferred margin recovery targets without a clear FY27 timeline.
₹3,234 Cr
+16.9% YoY (beat 10–12% guidance)
₹180 Cr
+10.0% YoY (lag revenue growth)
11%
–40bps YoY; target 13–14% deferred
~18–19%
Reported 26% H1 includes 4–5% forex
LT Foods delivered the headline: revenue surged 16.9% year-on-year, handily beating the prior guidance of 10–12% basmati growth. But the profit trajectory tells a harder story. Net profit grew only 10% — a full 7 points slower than revenue — because EBITDA margin compressed 40 basis points despite premium pricing power. This is the gap the call was meant to close.
Where the profit lagged the headline
Gross margin slipped 170 basis points year-on-year to 32.5%, the primary culprit. Freight cost inflation — particularly in the Middle East, the company's second-largest region at 9% of consolidated revenue — added 40 basis points of headwind. Management noted: 'the quarter was significantly impacted by supply disruptions, which constrained inventory flow into the region and a sharp escalation in freight cost further raised the landed cost.' Paddy and rice procurement costs rose on global demand, and the company absorbed a portion of landed-cost inflation before passing it to customers. Meanwhile, brand advertising spend spiked 70 basis points to 2.5% of revenue in support of new category launches. On an organic basis, stripping forex (which accounted for 4–5% of the basmati value growth), basmati's true growth was closer to 18–19%, not the reported 26%.
Management described this as 'investment phase' — brand building and supply-chain optimization now, margin recovery later. That framing deserves scrutiny, because the numbers don't yet support it.
Basmati segment delivered 26% value growth
Includes 4–5% forex tailwind; organic closer to 18–19%
Overstated
Middle East continues 15% growth trajectory
Actually 25% growth in H1, but supply disruptions and $50–$200/ton freight inflation weighed heavily
Supported (but context critical)
EBITDA margin recovery underway
11% in Q2, down from 11.4% YoY; H1 at 11.2% vs 11.7% prior year
Contradicted
Working capital efficiency improving
Inventory days 159 vs 187; payable days 26 vs 29; WC days 143 vs 174 YoY
Supported
Brand investments driving market share gains
Household reach 56.2 lakh → 67.5 lakh (+19%); branded portfolio +1.3% with 140bps market share gain
Supported
What changed on this call
The most material shift: margin guidance has been softened. On the prior call, management had guided toward 11.5%–12% EBITDA margins. This quarter, with reported EBITDA at 11%, management sidestepped a reaffirmation. Instead, the discussion shifted to 13–14% margins as a future state, contingent on three investment-phase segments (Europe, Middle East, RTH) scaling simultaneously — a timeline management declined to specify. When analyst Saurabh Beria directly pressed on FY27 guidance, MD Ashwani Kumar Arora responded: 'we are very confident on our business model… once all these markets scale, we are very optimistic the margin profile will change.' No numbers, no dates — a classic deferral.
Two other timelines have slipped. Ready-to-Heat (RTH) facility profitability, previously guided as breakeven at ₹400 Cr revenue, is now expected 'next year' (FY28, not FY27) as the segment scales from ₹102 Cr H1 revenue. Nature Bio Foods, transitioning from ingredient sourcing to consumer-facing organic, is creating near-term revenue pressure as the intermediary-led model is phased out. Both are structurally sound but longer-dated than prior expectations.
Sequential basmati volume growth slowed to 6% quarter-on-quarter, half the year-on-year rate of 11%. Analyst Bhavi Chauhan flagged 'modest sequential growth,' raising the question of demand elasticity at higher paddy prices.
Basmati revenue growth beat guidance by 7pp (16.9% vs 10–12%)
North America (50% of revenue) accelerating at +21% with strong brand momentum
ROCE improved to 22.4% from 22%; cash position ₹247 Cr from working capital release
Household brand reach expanded 56.2 lakh to 67.5 lakh (+19% YoY); market share +140bps
EBITDA margin compressed 40bps YoY despite pricing power; no H2 recovery guardrail given
Sequential basmati volume growth slowed to 6% QoQ; demand elasticity at risk
Forex tailwind of 4–5% embedded in headline basmati growth; organic closer to 18–19%
RTH and Organic timelines pushed; 13–14% margin target is multi-year, not FY27
Freight cost pass-through delayed; Middle East absorbing $200/ton
HighMiddle East is 9% of revenue; full benefit of mitigation steps not yet visible. If customer pass-through slows, consolidated margin pressure extends longer.
Margin guidance credibility; 13–14% target is multi-year ramp without FY27 timeline
HighNo explicit reaffirmation of 11.5%–12% margins for FY27. Management deflected when directly pressed. Credibility hinges on Q3 and Q4 delivery.
Sequential basmati volume growth decelerating (6% QoQ vs 11% YoY)
MediumSuggests demand elasticity concern as paddy prices stay elevated. If volume growth falls below guidance, revenue credibility erodes.
RTH profitability deferred to FY28; ₹400 Cr breakeven milestone not yet clearly on track
MediumCapex deployment risk; consolidated margin recovery hinges on three investment-stage segments maturing simultaneously.
Nature Bio Foods remodeling creating near-term revenue drag; structural margin upside post-transition unclear
MediumSegment in transition from sourcing-led to consumer-focused. Near-term revenue pressure; medium-term upside not yet quantified.
Forex tailwind (4–5% of basmati growth) may reverse if INR strengthens
LowCurrent INR depreciation a tailwind; policy or capital flows could reverse realized pricing gains. Asymmetric but not imminent.
1 · Q3 freight cost pass-through realization
The key catalyst. Middle East and Europe should show margin benefit as paddy cycle matures and pricing initiatives take hold. If EBITDA margin stays flat or falls, guidance credibility breaks.
2 · Sequential basmati volume inflection
Q3 will show whether the 6% QoQ slowdown was seasonal or structural. Management needs to demonstrate demand is elastic enough to absorb price gains without volume collapse.
3 · RTH capacity ramp and Organic remodeling progress
Both are contingent on H2 execution. Any further timeline slip raises the question of whether scale-up economics are realistic or aspirational.
How the street is positioned
The stock is down 20.8% from its all-time high of ₹518.55, trading at ₹410.55 with RSI neutral at 54.4. Foreign institutional investors have trimmed holdings by 53 basis points to 8.21% in the latest quarter, while domestic institutions added 54 basis points to 10.84% — a modest divergence suggesting offshore caution but steady domestic accumulation. The tape and flows confirm the fundamental story: the market is positioned defensively, waiting for confirmation that margin recovery is real, not aspirational.
This is a company executing a steady, multi-year geographic and segment expansion. The quarter proves basmati growth is real — 17% revenue growth, beat guidance. But the profit lag and margin compression are not transient; they are the cost of brand-building and supply-chain re-optimization in a period of freight inflation. The honest read is execution staying on track, not accelerating.
The single number to track from here is Q3 EBITDA margin. If it recovers toward 11.4% or higher as freight mitigation kicks in, management's multi-year story gains credibility and the stock has upside from current levels. If it stays flat or compresses further, the bear case — that margin recovery is aspirational and deferred indefinitely — becomes hard to dismiss. At ₹410.55, down one-fifth from its high, the stock is fairly priced for steady-state execution. Upside awaits proof.
Informational and educational content only. Not investment advice.